Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events

Subsequent Events
3 Months Ended
Mar. 31, 2015
Subsequent Events [Abstract]  
Subsequent Events

12. Subsequent events

On April 6, 2015, the Company executed a product development agreement with RRD International, LLC (“RRD”), a clinical product development organization, which provides the Company with integrated and expert level strategic, clinical, medical, regulatory and operational management and execution of its CF-301 clinical program. In conjunction with the execution of the agreement, the Company issued 28,445 shares of its common stock to RRD for the initial $150,000 of services provided.